Jordi Remon, Thoracic Oncologist at CIOCC Barcelona, shared a post on X:
“HER2 TKI for HER2m NSCLC are real again
Zongeritinib (the 2nd xombie ) outstanding activity in 1st Line (n=74, 30% Brain mets) with most G1-2 AEs (better safety than sebavertinib)
Ready to replace 1st line CTIO? Awaiting for the ph3 trial BeamionLung02 zonge vs SoC.”
You can also read: ESMO 2025 Day 1 Highlights Not to Miss
